Pilot Randomized Trial of Bupropion for Adolescent Methamphetamine Abuse/Dependence



      To perform a pilot clinical trial of bupropion for methamphetamine abuse/dependence among adolescents.


      Nineteen adolescents with methamphetamine abuse (n = 2) or dependence (n = 17) were randomly assigned to bupropion SR 150 mg twice daily or placebo for 8 weeks with outpatient substance abuse counseling.


      Bupropion was well-tolerated except for one female in the bupropion group who was hospitalized for suicidal ideation during a methamphetamine relapse. Adolescents receiving bupropion and females provided significantly fewer methamphetamine-free urine tests compared to participants receiving placebo (p = .043) and males (p = .005) respectively.


      Results do not support the feasibility of additional trials of bupropion for adolescent methamphetamine abuse/dependence. Future studies should investigate the influence of gender on adolescent methamphetamine abuse and treatment outcomes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Adolescent Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Johnston L.D.
        • O'Malley P.M.
        • Bachman J.G.
        • et al.
        Monitoring the future: National results on adolescent drug use: Overview of key findings, 2011.
        Institute for Social Research, The University of Michigan, Ann Arbor2012
        • Marshall B.D.
        • Werb D.
        Health outcomes associated with methamphetamine use among young people: a systematic review.
        Addiction (Abingdon, England). 2010; 105: 991-1002
        • King G.
        • Alicata D.
        • Cloak C.
        • et al.
        Neuropsychological deficits in adolescent methamphetamine abusers.
        Psychopharmacology (Berl). 2010; 212: 243-249
        • Elkashef A.M.
        • Rawson R.A.
        • Anderson A.L.
        • et al.
        Bupropion for the treatment of methamphetamine dependence.
        Neuropsychopharmacology. 2008; 33: 1162-1170
        • Shoptaw S.
        • Heinzerling K.G.
        • Rotheram-Fuller E.
        • et al.
        Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.
        Drug Alcohol Depend. 2008; 96: 222-232
        • Woody G.E.
        • Poole S.A.
        • Subramaniam G.
        • et al.
        Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
        JAMA. 2008; 300: 2003-2011
        • Gray K.M.
        • Carpenter M.J.
        • Baker N.L.
        • et al.
        Bupropion SR and contingency management for adolescent smoking cessation.
        J Subst Abuse Treat. 2011; 40: 77-86
        • Auten J.D.
        • Matteucci M.J.
        • Gaspary M.J.
        • et al.
        Psychiatric implications of adolescent methamphetamine exposures.
        Pediatr Emerg Care. 2012; 28: 26-29
        • Gonzales R.
        • Ang A.
        • McCann M.J.
        • et al.
        An emerging problem: methamphetamine abuse among treatment seeking youth.
        Substance Abuse. 2008; 29: 71-80
        • Heinzerling K.G.
        • Shoptaw S.
        Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.
        Gender Medicine. 2012; 9: 112-120